| Prev Close | 22.52 |
| Open | 22.42 |
| Day Low/High | 22.02 / 24.26 |
| 52 Wk Low/High | 7.73 / 26.77 |
| Volume | 3.92M |
| Avg Volume | 1.70M |
Invitae Corp. (NVTA)
23.49
0.97
4.30
NYSE : Health Services
| Exchange | NYSE |
| Shares Outstanding | 92.34M |
| Market Cap | 2.10B |
| EPS | -1.90 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
3 Small Biotechs to Watch as Earnings Season Winds Down
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
Here Are 3 Small-Cap Names for Biotech Investors to Consider
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
Consider These Diagnostic Testing Firms
Diagnostic firms can have an advantage of recurring revenue streams.
Names to Watch Amid Biotech's Nascent Rally
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.
3 Small Biotechs Turn on the Revenue Jets
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
3 of My Favorite Medical Diagnostic Plays
These equities have been in rally mode since April.
3 Favorite Biotech Stocks for the Second Quarter
Your questions are answered in our latest addition of the biotech mailbag.
Lackluster Market on Tons of Earnings
Some good discussions today on the Daily Diary. Look forward to continuing the conversation tomorrow as we look to wrap up a solid week for equities. Market was lackluster today but had a ton of earnings reports to take into account. Not to mention ...
Shark Bites: Traders Could Trip on This Market Bounce
V-shaped moves are more common than they used to be.
Three Health-Care Growth Plays
Eagle Pharmaceuticals, Invitae and Celgene should do well this year and are attractively priced.
Invitae Inviting as Undervalued Growth Play
The rapidly growing genetic testing concern is executing its growth plan marvelously.
Biotech, Health Care Likely to Drive IPOs at NYSE in Second Half
Garvis Toler, head of global capital markets at the NYSE, reviews the landscape of IPOs during the first half of 2015 and previews what's in store for the second half.
